Strategic partnerships Sepragen’s collaboration with Shimadzu Group signals active interest from global equipment vendors and potential for co-selling, integration, or joint development opportunities in biopharma markets in Asia and beyond.

Scale-up capabilities Market need exists for rapid scale-up from lab to production with minimal footprint and capex impact, aligning well with customers pursuing fast deployment of bioprocess equipment and single-use or continuous chromatography systems.

Broad customer base Existing adoption by industry leaders across four continents and 24 FDA-approved drugs indicates strong referenceability and a credible platform to upsell additional modules, services, and higher-end chromatography solutions.

Vaccine manufacturing tie-ins Proven capacity to enable large-dose production for vaccines positions Sepragen to target contract manufacturers and vaccine producers seeking efficient, scalable equipment for ongoing or new vaccine programs.

Growth-ready funding Revenue scale and targeted product expansion into integrated chromatography and buffer systems present opportunities to pursue strategic investments, partnerships, or grant-driven programs with biotech firms expanding facilities and capabilities.